What's Happening?
The Jackson Laboratory, in collaboration with the Broad Institute and other partners, has been awarded up to $34.5 million by the Advanced Research Projects Agency for Health (ARPA-H) to advance a gene editing platform for pediatric epilepsies and rare
CNS diseases. The funding supports the Pediatric Epilepsies & Rare CNS (PERC) Gene Editing Platform, which aims to develop precision genetic medicines for severe childhood neurologic diseases. The project will initially focus on alternating hemiplegia of childhood and Dravet syndrome, with goals to advance gene-editing approaches, generate evidence for human studies, and create a scalable platform for additional rare diseases.
Why It's Important?
This initiative addresses a critical need for effective treatments for rare pediatric neurological disorders, which often have limited therapeutic options. By developing a systematic and scalable approach to gene editing, the project could revolutionize the treatment landscape for rare diseases, offering hope to affected children and their families. The collaboration between leading research institutions and the support from ARPA-H highlights the importance of public-private partnerships in advancing medical research and innovation. Success in this project could pave the way for broader applications of gene editing in other rare and complex diseases.
What's Next?
The project will focus on advancing gene-editing techniques and building a regulatory pathway for clinical applications. Researchers will work on preclinical models to demonstrate safety and efficacy, aiming to move towards first-in-human studies. The collaboration will also explore expanding the platform to address additional rare CNS diseases, potentially transforming the approach to genetic medicine. Continued support and successful outcomes could lead to increased investment in similar initiatives, further accelerating the development of precision therapies for rare diseases.
